Literature DB >> 9786316

Promising new agents for treatment of patients with colorectal cancer.

D D Von Hoff1.   

Abstract

Colorectal cancer continues to be a major problem. There are a number of new agents with promising clinical activity, including the multitargeted antifolate LY 231514 and the thymidylate synthesis inhibitor capecitabine. In addition, other agents have shown promising preclinical activity against the disease: 6-hydroxymethylacylfulvene (HMAF; MGI 114), LY 295501, bizelesin (U-7779; NSC615291), and ONYX-015. Finally, several agents may prevent colorectal cancer through prevention of the formation of colorectal polyps (eg, cyclooxygenase inhibitors).

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9786316

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  3 in total

Review 1.  Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Authors:  Pierpaolo Correale; Maria Grazia Cusi; Lucia Micheli; Cristina Nencini; Maria Teresa Del Vecchio; Francesco Torino; Angelo Aquino; Enzo Bonmassar; Guido Francini; Giorgio Giorgi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

2.  Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells.

Authors:  Aye Aye Thant; Yanyuan Wu; Jane Lee; Dhruva Kumar Mishra; Heather Garcia; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

3.  A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.

Authors:  P Correale; S Messinese; M Caraglia; S Marsili; A Piccolomini; R Petrioli; F Ceciarini; L Micheli; C Nencini; A Neri; G Vuolo; A Guarnieri; A Abbruzzese; S D Prete; G Giorgi; G Francini
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.